Aratana Therapeutics Acquires Okapi Sciences NV
6 January 2013, Kansas City, USA and Leuven, Belgium – Aratana Therapeutics, Inc. (Nasdaq: PETX) today announced, that it has acquired Okapi Sciences NV. The strategic acquisition of Okapi further enhances Aratana’s leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Please find the full press release here.